Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

21%

3 of 14 completed with results

Key Signals

3 with results93% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (9)
P 2 (2)
P 3 (1)
P 4 (1)

Trial Status

Completed14
Unknown6
Recruiting1
Terminated1
Not Yet Recruiting1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT04058743Not ApplicableTerminated

Nickel Sensitivity

NCT07391917Not Yet RecruitingPrimary

Human Seminal Plasma Allergy: Quality of Life

NCT06957496Not ApplicableCompleted

Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization

NCT06527937Phase 2CompletedPrimary

Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome

NCT06065137Not ApplicableCompletedPrimary

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

NCT04761822Phase 2Completed

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT05532566Not ApplicableRecruitingPrimary

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

NCT06011603Phase 4CompletedPrimary

Prineo Sensitivity Dressing Study

NCT05670756Completed

Preoperative Survey to Evaluate Patient Allergy

NCT05533385Not ApplicableCompleted

Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

NCT05284253Not ApplicableUnknownPrimary

Is There an Allergy to Pure Metallic Gold Microparticles?

NCT05185479CompletedPrimary

Analysis of Adverse Events in Anesthesia Using Artificial Intelligence

NCT05605795UnknownPrimary

Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test

NCT05462444Unknown

Development of Personalized Balanced Nutrition Concept Through an IT Platform

NCT05367531Not ApplicableUnknown

Assessment of Injectable Medication Platforms

NCT05649891Not ApplicableUnknown

Checklists Resuscitation Emergency Department

NCT05185362UnknownPrimary

Epidemiology of Pecan Nut Allergy

NCT04510376Not ApplicableCompletedPrimary

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

NCT03942692Completed

What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction

NCT03489694CompletedPrimary

Repeatability and Reproducibility of Skin Test Endpoint Titration

Scroll to load more

Research Network

Activity Timeline